NCT01513174View on ClinicalTrials.gov

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Gefitinib

Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression

DRUG

Olaparib

Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.

Trial Locations (5)

Unknown

H. Germans Trias i Pujol, Badalona

H. Teresa Herrera, A Coruña

H. Gen. Universitario de Alicante, Alicante

H. Vall d'Hebrón, Barcelona

08908

ICO Hospitalet, L'Hospitalet de Llobregat

All Listed Sponsors

lead

Spanish Lung Cancer Group

OTHER

NCT01513174 - Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone | Biotech Hunter | Biotech Hunter